Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

NCT03969849 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Birch Pollen Allergy

Interventions

DRUG: REGN5713-5714-5715
DRUG: Matching placebo

Sponsor

Regeneron Pharmaceuticals